Cambridge-based biotech company Sphere Fluidics has announced the appointment of a new CEO, following the retirement of co-founder Dr Frank F. Craig.
Sphere Fluidics develops cell analysis systems based on its proprietary microfluid platform. Called picodroplet, the company’s technology is used to support biomedical research and drug development.
The firm has been run since its launch in 2010 by Craig, who founded Sphere Fluidics alongside Prof Chris Abell and Prof Wilhelm Huck.
Following the announcement of Craig’s retirement, Sphere Fluidics – which raised $40m (£32m) in late 2021 – has brought on Dale Levitzke as its new chief executive.
“Sphere Fluidics’ picodroplet technology and microfluidics platforms are transforming single cell analysis and isolation capabilities, bringing new possibilities to biopharmaceutical research and development,” Levitzke said.
“I look forward to joining the team to continue to lead and drive its ambitious plans for commercial growth, international expansion, and eventual exit.”
Levitzke has held executive roles at a handful of prominent biotech firms. He was previously a senior vice president at Vizgen and oversaw sales and marketing at Dropworks, later acquired by Bio-Rad for £100m.
“It has been a privilege to serve as CEO of Sphere Fluidics for over 14 years and I am delighted to pass the baton onto Dale as he takes over as CEO,” added Craig.
“His experience of driving innovation and commercial success will be pivotal to advancing Sphere Fluidics’ ambitious strategic vision and plans for commercial growth.”